Antistoff selektivt for en tumornekrosefaktor-relatert apoptose-induserende ligand reseptor og anvendelser derav

• Main Authors: KIMBERLY ROBERT P, ZHOU TONG, KOOPMAN WILLIAM J, ICHIKAWA KIMIHISA
• Format: Patent
• Language: Norwegian
• Published: 18.12.2002
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; VINEGAR; WINE

2005 -09- o 6 S a m m e n d r a g Et antistoff ifølge foreliggende oppfinnelse interagerer med human DR5 for å produsere agonistiske eller antagonistiske effekter nedstrøms for reseptoren omfattende hemning av celleproliferasjon og apoptose. A purified antibody is disclosed which specifically binds a TRAIL receptor DR5, wherein said antibody: a) has apoptosis-inducing activity in the absence of secondary crosslinking in target cells expressing DR5 in vitro, wherein the apoptosis-inducing activity in vitro is characterized by less than 70% target cell viability at an antibody concentration of 2.5 pg/ml; b) has tumoricidal activity against tumor cells expressing DR5 in vivo; and c) does not bind TRAIL receptor DR4, DcR1, or DcR2.